Table 2.
Risk estimates demonstrated as hazard ratios (HR) with 95% confidence intervals (CI) and absolute rate difference (ARD) of all cancers and stratified by cancer type in PSC patients (n = 1432) and general population comparators (n = 14,437)
| Cancer type | PSC patients | Comparators | ARD | HR | 95% CI | ||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N/100,000 | |||
| Any first cancer | 285 | 19.9 | 1085 | 7.5 | 1111.1 | 3.8 | 3.3–4.3 |
| Hepatobiliary | 140 | 9.8 | 16 | 0.1 | 732.7 | 120.9 | 72.0–203.1 |
| Colorectal | 68 | 4.8 | 130 | 0.9 | 307.9 | 7.5 | 5.6–10.1 |
| Esophageal | 1 | 0.07 | 10 | 0.07 | 1.0 | 1.4 | 0.2–11.1 |
| Gastric | 5 | 0.4 | 18 | 0.1 | 18.6 | 4.1 | 1.5–11.3 |
| Small bowel | 3 | 0.2 | 2 | 0.01 | 14.8 | 21.1 | 3.5–128.2 |
| Pancreatic | 7 | 0.5 | 13 | 0.1 | 31.1 | 8.0 | 3.2–20.2 |
| Lung cancer | 7 | 0.5 | 77 | 0.5 | 4.4 | 1.3 | 0.6–2.8 |
| Breast cancer | 8 | 0.6 | 116 | 0.8 | − 6.7 | 0.9 | 0.5–1.9 |
| Female genital | 19 | 4.3a | 149 | 3.4a | 37.2 | 1.6 | 1.0–2.6 |
| Male genital | 16 | 1.6b | 248 | 2.5b | − 20.2 | 0.9 | 0.6–1.6 |
| Kidney and bladder | 3 | 0.2 | 64 | 0.4 | − 11.1 | 0.7 | 0.2–2.2 |
| Melanoma | 8 | 0.6 | 91 | 0.6 | 3.9 | 1.2 | 0.6–2.4 |
| Lymphoma | 11 | 0.8 | 51 | 0.4 | 36.3 | 3.0 | 1.6–5.7 |
| Myeloma and leukemia | 3 | 0.2 | 46 | 0.3 | − 3.6 | 0.9 | 0.3–2.9 |
| Other | 18 | 1.3 | 155 | 1.1 | 29.32 | 1.6 | 1.0–2.6 |
aPercentage of number of females
bPercentage of number of males